The scale of the problem is considerable. Breast cancer accounted for approximately 2.308 million new cases worldwide in 2022, representing 11.6 percent of all new cancer diagnoses and making it the second most common cancer globally. Chemotherapy remains a cornerstone of treatment for early-stage disease, but its toxicities—ranging from severe neutropenia to peripheral neuropathy—can force dose reductions, treatment interruptions, or complete discontinuation, ultimately compromising prognosis and quality of life.

The review, led by researchers at The First Affiliated Hospital of Jinzhou Medical University in China, synthesizes evidence on how body composition indicators relate to chemotherapy toxicity. The authors trace the evolution of assessment methods from crude anthropometric surrogates—such as the five percent weight-loss threshold once used to mark cachexia in the 1970s—to today’s sophisticated imaging tools. Computed tomography, magnetic resonance imaging, dual-energy X-ray absorptiometry (DXA), and bioelectrical impedance analysis (BIA) now allow clinicians to quantify skeletal muscle, visceral fat, subcutaneous fat, and muscle quality with remarkable precision, and artificial intelligence is increasingly automating these analyses.

Central to the discussion is the distinction between lean body mass and fat-free mass, terms that are chemically similar but historically defined differently—lean body mass includes polar lipids, while fat-free mass does not. The authors recommend prioritizing fat-free mass in research to improve scientific rigor. They also highlight the third lumbar vertebra skeletal muscle index (L3-SMI), calculated from a single CT slice as skeletal muscle area at L3 divided by height squared, which was first reported in 2008 as an independent predictor of chemotherapy toxicity. Notably, DXA-derived appendicular lean mass indices and CT-based L3-SMI correlate only moderately (r = 0.66, p < 0.001), meaning the two metrics are not directly interchangeable—a source of ongoing confusion in the literature.

The mechanistic story is where the review becomes particularly compelling. Muscle is highly vascularized and metabolically active, so patients with greater lean mass tend to metabolize and clear drugs more efficiently. Pharmacokinetic studies bear this out: each additional kilogram of lean body mass increased doxorubicin clearance by roughly 19 percent in an exploratory study, and lower muscle mass was associated with reduced volume of distribution and higher peak plasma concentrations of paclitaxel. Low lean mass can also reduce creatinine production, causing the Cockcroft-Gault formula to overestimate renal function—a hazard flagged by a creatinine clearance to glomerular filtration rate ratio of 1.23 as a warning threshold for carboplatin overdose and severe thrombocytopenia.

Fat tells a different, sometimes paradoxical story. Lipophilic agents such as paclitaxel and docetaxel distribute into adipose compartments, while hydrophilic drugs like fluoruracil and cyclophosphamide prefer water-rich lean tissue. Visceral fat volume was positively correlated with doxorubicin exposure (r² = 0.324, P < 0.001) and grade 4 leukopenia in Asian breast cancer patients. Experimental work suggests adipocytes can increase anthracycline levels by 30 percent by upregulating CBR1 and AKR metabolic enzymes, sustaining the release of toxic metabolites. Visceral fat-derived free fatty acids also reach the liver through the portal circulation, potentially inducing hepatic steatosis and impairing drug metabolism—liver attenuation on CT, inversely related to fat content, predicted epirubicin exposure in one analysis.

The clinical correlations are striking. In early-stage breast cancer patients, higher fat mass increased the risk of toxicity-induced modification of treatment—dose reductions, interruptions, cessation, or regimen changes—while higher relative lean mass reduced that risk. Obese patients (BMI ≥ 30 kg/m²) experienced docetaxel dose reductions at 18 percent versus 5 percent in nonobese patients (p = 0.008), along with lower pathological complete response rates and shorter disease-free survival. Sarcopenia, which affects an estimated 40 to 45 percent of breast cancer patients, independently predicted severe toxicity: sarcopenic patients receiving epirubicin-cyclophosphamide experienced severe laboratory adverse events at 70 percent versus 22.2 percent (OR 7.9, p = 0.004). Myosteatosis—fat infiltration within muscle, visible as lower Hounsfield units on CT—was associated with reduced relative dose intensity and with dose reductions, early treatment interruption, and hospitalization.

Perhaps the most alarming phenotype is sarcopenic obesity, the coexistence of excessive adiposity with reduced muscle mass and impaired function, as defined by the ESPEN-EASO consensus. In early-stage breast cancer patients receiving anthracycline and taxane chemotherapy, sarcopenic obesity independently predicted severe toxicity, tripling the risk of grade 3–4 hematological toxicity and raising the risk of neutropenia 3.5-fold. Prevalence estimates vary widely—from 0.8 to 22.3 percent in general populations—partly because diagnostic thresholds remain inconsistent, with more than 14 sarcopenia cutoffs reported across oncology studies.

The review does not shy away from the field’s contradictions. Adipose tissue can exert bidirectional effects: in one study of 120 patients receiving neoadjuvant chemotherapy, higher fat percentage correlated with reduced neurotoxicity risk, though no significant interaction appeared in platinum-containing regimens. Chemotherapy itself alters body composition over time, and most studies rely only on baseline measurements, potentially underestimating true toxicity risk. The authors also point to the LEANOX randomized controlled trial as proof of concept: lean body mass-based oxaliplatin dosing at 3.09 mg/kg increased the proportion of patients free of grade ≥ 2 peripheral neurotoxicity from 42.1 to 67.2 percent, without compromising long-term survival—evidence that composition-guided dosing is clinically practicable, at least for some drugs.

Looking forward, the authors call for regimen-specific pharmacokinetic modeling across anthracyclines, taxanes, and platinum agents; risk stratification that integrates breast cancer subtypes with visceral-to-subcutaneous fat ratios and muscle indices; prospective trials of nutritional optimization and resistance training in high-risk patients; and international consensus on definitions and cutoffs, potentially enriched with multi-omics biomarkers. They suggest DXA, a low-radiation whole-body scan, could eventually replace CT for routine body composition assessment in early cancer, where L3-level CT scans are not standard. Until prospective, breast cancer-specific studies validate these approaches, body surface area dosing will remain the norm—but the writing is on the wall, and it is written in muscle and fat.

Subject of Research: The relationship between body composition and chemotherapy-related toxicity in early-stage breast cancer

Article Title: Body composition and chemotherapy-related toxicities in early-stage breast cancer: implications for personalized treatment strategies

Article References: Body composition and chemotherapy-related toxicities in early-stage breast cancer: implications for personalized treatment strategies. (n.d.). https://doi.org/10.1007/s44178-026-00287-4

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00287-4

Keywords: breast cancer, body composition, chemotherapy toxicity, sarcopenia, sarcopenic obesity, lean body mass, visceral fat, myosteatosis, pharmacokinetics, personalized dosing, DXA, CT imaging

The biological heterogeneity of TNBC complicates its classification and treatment further. Unlike hormone receptor-positive breast cancers, TNBC lacks uniform molecular targets, exhibiting a spectrum of genetic and epigenetic aberrations. These variations have propelled researchers to explore detailed genomic and transcriptomic landscapes to identify exploitable vulnerabilities. Recent advances have uncovered distinct molecular subtypes within TNBC, each characterized by unique expression patterns of immune, mesenchymal, and proliferative genes, shedding light on differential responses to emerging therapeutic agents.

Intratumoral heterogeneity also presents a significant barrier. The dynamic cellular ecosystem within TNBC tumors fosters adaptability and drug resistance, challenging conventional treatment paradigms. Cancer stem-like cells, a subpopulation within TNBC tumors, possess enhanced self-renewal and survival capabilities, contributing to relapse and metastasis. Such insights have shifted research focus toward eradicating these resilient cellular niches through novel therapeutics and precision medicine approaches.

Current standard-of-care primarily involves cytotoxic chemotherapy, including anthracyclines and taxanes, which, despite improving survival rates, often yield transient responses and substantial toxicity. The absence of target-specific therapies accentuates the urgency for novel drug candidates and combinatorial regimens that can circumvent resistance mechanisms and minimize adverse effects. Immunotherapy has recently emerged as a beacon of hope in this landscape, harnessing the patient’s immune system to recognize and destroy malignant cells.

Checkpoint inhibitors targeting PD-1/PD-L1 pathways have demonstrated promising efficacy in clinical trials for TNBC, especially when combined with chemotherapy. These agents reinvigorate exhausted T-cells, facilitating sustained anti-tumor immune responses. However, not all patients derive benefit, prompting intense investigation into biomarkers that predict therapeutic response and strategies to modulate the tumor microenvironment favorably.

Beyond immunotherapy, poly (ADP-ribose) polymerase (PARP) inhibitors have revolutionized the treatment of BRCA-mutated TNBC. These agents exploit defective DNA repair pathways by inducing synthetic lethality, effectively killing cancer cells harboring homologous recombination deficiencies. The clinical integration of PARP inhibitors represents a paradigm shift, emphasizing the importance of genetic testing and personalized medicine in optimizing patient outcomes.

Advancements in high-throughput sequencing technologies have revolutionized the understanding of TNBC at a molecular level. Multi-omics approaches integrating genomics, proteomics, and metabolomics have unveiled intricate networks driving tumor progression and resistance. These comprehensive datasets facilitate the identification of novel drug targets and the development of predictive models for treatment stratification, marking a significant step towards precision oncology.

In parallel, the exploration of antibody-drug conjugates (ADCs) offers a new frontier in TNBC therapy. ADCs combine the specificity of monoclonal antibodies with potent cytotoxic agents, delivering targeted cell killing while sparing normal tissue. Early-phase clinical trials report encouraging activity of ADCs targeting surface markers specifically upregulated in TNBC cells, heralding a new class of therapeutics that blend immunotherapy with chemotherapy’s efficacy.

The role of the tumor microenvironment in shaping TNBC progression is now recognized as pivotal. Components such as cancer-associated fibroblasts, immune infiltrates, and extracellular matrix elements dynamically interact with tumor cells, influencing proliferation, invasion, and immune evasion. Therapeutic strategies aimed at remodeling the microenvironment are under active investigation, aiming to diminish tumor-promoting signals and enhance treatment susceptibility.

Nanotechnology-based drug delivery systems are gaining traction in TNBC research, offering solutions to conventional limitations such as poor bioavailability and systemic toxicity. Nanocarriers can be engineered to home in on tumor-specific markers, release payloads in a controlled manner, and overcome biological barriers, thereby enhancing therapeutic indices. Integration of nanomedicine with immunomodulatory and molecularly targeted agents could redefine future therapeutic landscapes.

Emerging data also points to the significant impact of cancer metabolism in TNBC etiology and progression. Aberrant metabolic pathways, including enhanced glycolysis and altered lipid metabolism, support the energetic and biosynthetic demands of rapidly dividing tumor cells. Targeting these metabolic dependencies presents a promising avenue to disrupt tumor growth and sensitize cancer cells to existing treatments.

Preclinical models, such as patient-derived xenografts and organoids, provide invaluable platforms for elucidating TNBC biology and evaluating novel therapies. These models recapitulate human tumor complexity more faithfully than traditional cell lines, enabling more predictive assessments of drug efficacy and resistance mechanisms. The refinement and widespread adoption of such models are expected to accelerate translational efforts.

Despite these advances, significant obstacles remain before realizing the full potential of emerging TNBC therapies. Challenges include overcoming intra- and inter-tumoral heterogeneity, managing toxicity profiles, and ensuring affordable access to cutting-edge treatments globally. Collaborative efforts spanning academia, industry, and clinical disciplines are essential to translate bench discoveries into transformative clinical outcomes.

Early detection strategies tailored to TNBC could markedly improve survival rates, yet biomarker development lags behind. Innovations in liquid biopsy technologies, including circulating tumor DNA and exosome profiling, offer non-invasive means of disease monitoring and early relapse detection. Incorporating these tools into clinical practice could personalize treatment regimens and improve prognostication.

In conclusion, triple-negative breast cancer epitomizes the intersection of complexity and urgency in cancer research. Its distinct molecular features, clinical aggressiveness, and therapeutic challenges galvanize efforts toward innovative interventions. The amalgamation of molecular insights, advanced therapeutics, and precision medicine holds promise for converting TNBC from a devastating diagnosis into a manageable disease, potentially reshaping the future landscape of oncological care.

Subject of Research: Triple-negative breast cancer: biological challenges, molecular advances, and therapeutic developments

Article Title: Triple-negative breast cancer: challenges, advances, and promising therapeutic interventions

Article References:
Sood, D., Kaur, C., Kumar, N. et al. Triple-negative breast cancer: challenges, advances, and promising therapeutic interventions. Med Oncol 42, 506 (2025). https://doi.org/10.1007/s12032-025-03066-9

Image Credits: AI Generated